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Abstract
 
Progressive loss of CD4
 
1
 
 T lymphocytes, accompanied by
opportunistic infections characteristic of the acquired im-
mune deficiency syndrome, has been reported in the ab-
sence of any known etiology. The pathogenesis of this syn-
drome, a subset of idiopathic CD4
 
1
 
 T lymphocytopenia
(ICL), is uncertain. We report that CD4
 
1
 
 T cells from
seven of eight ICL patients underwent accelerated pro-
grammed cell death, a process facilitated by T cell receptor
cross-linking. Apoptosis was associated with enhanced ex-
pression of Fas and Fas ligand in unstimulated cell popula-
tions, and partially inhibited by soluble anti-Fas mAb. In
addition, apoptosis was suppressed by aurintricarboxylic
acid, an inhibitor of calcium-dependent endonucleases and
proteases, in cells from four of seven patients. The in vivo
significance of these findings was supported by three fac-
tors: the absence of accelerated apoptosis in persons with
stable, physiologic CD4 lymphopenia without clinical im-
mune deficiency; detection of serum antihistone H2B au-
toantibodies, one consequence of DNA fragmentation, in
some patients; and its selectivity, with apoptosis limited to
the CD4 population in some, and occurring among CD8
 
1
 
 T
cells predominantly in those individuals with marked deple-
tion of both CD4
 
1
 
 and CD8
 
1
 
 peripheral T lymphocyte
subsets. These data suggest that patients with idiopathic
loss of CD4
 
1
 
 T lymphocytes linked to clinical immune sup-
pression have evidence for accelerated T cell apoptosis in
vitro that may be pathophysiologic and amenable to ther-
apy with apoptosis inhibitors. (
 
J. Clin. Invest.
 
 1996. 97:672–
680.) Key words: aurintricarboxylic acid 
 
• 
 
cell death, pro-
grammed 
 
•
 
 immunologic deficiency syndromes 
 
•
 
 T lym-
phocyte
 
Introduction
 
Marked CD4
 
1
 
 T lymphopenia in the absence of HIV infec-
tion has been documented by our group (1) and others (2, 3).
This syndrome is termed idiopathic CD4
 
1
 
 T lymphocytopenia
(ICL)
 
1
 
 by the U.S. Centers for Disease Control and Prevention
(2), and severe unexplained HIV seronegative immune sup-
pression (SUHIS) by the World Health Organization (4). It is
defined by an absolute CD4 count 
 
,
 
 300/mm
 
3
 
 or 
 
,
 
 14%, ei-
ther alone (ICL) or accompanied by clinical signs and symp-
toms of cellular immune deficiency (SUHIS). The etiology of
this syndrome is unclear and, given the lack of risk factors for
acquisition of HIV infection in most individuals, absence of a
clear epidemiologic pattern, diversity of prodromes, and tran-
sient nature of many cases, almost certainly multifactorial.
We recently distinguished a subset of ICL patients mimick-
ing HIV disease: severe, prolonged decrement in peripheral
CD4
 
1
 
 T cells with progressive decline in such counts docu-
mented in some; CD4/CD8 T cell ratios 
 
# 
 
1; and a history of
opportunistic infections (5, 6). This finding served as the impe-
tus to investigate mechanisms associated with T cell loss in
HIV infection and other disorders which might also be etio-
logic in ICL.
Apoptosis of T lymphocytes in vitro, linked to transient T
cell loss in vivo, is a consequence of certain viral infections, in-
cluding lymphocytic choriomeningitis (7) and vaccinia (8) in
mice and EBV (9) in humans. It has also been reported in as-
sociation with HIV-1 (10, 11) in humans, although whether or
not direct HIV infection is required for this effect, and its spec-
ificity for CD4
 
1
 
 T cells, are subjects of debate (10–12). We
sought to test the hypothesis that apoptosis plays a role in ICL
associated with clinical immune deficiency and attempted to
relate the accelerated in vitro death of CD4
 
1
 
 T cells from
these individuals with expression of two molecules linked to
programmed cell death, Fas and Fas ligand (13). We also eval-
uated the ability of anti-Fas mAb and two drugs, aurintricar-
boxylic acid (ATA) and tamoxifen (TMX), known inhibitors
of two common pathways to apoptosis, Ca
 
2
 
1
 
-dependent endo-
nuclease activation and cAMP signalling, respectively, to miti-
gate this cell death. In vivo correlates were sought by assays
for circulating antihistone H2B autoantibodies, one conse-
quence of DNA fragmentation (12), and examination of lym-
phocytes from patients with stable, “physiologic” CD4 lym-
phopenia. Our results suggest the discrimination of a subset of
ICL patients with sustained T cell apoptosis that is clinically
relevant and may be amenable to therapy with inhibitors of
programmed cell death.
 
Methods
 
Patient selection. 
 
PBMC were prepared from heparinized venous
blood of eight ICL patients and four controls by density gradient cen-
trifugation (14). The clinical data and risk factors for retroviral infec-
tion, if any, are shown in Table I. Only one of the ICL patients, ICL-1,
has been previously reported (1). All subjects were seronegative for
HIV-1,-2, and human T cell lymphotropic virus types I, II by ELISA
and, HIV-1, by immunoblotting. No patient had an active infection at
the time of study. All were receiving trimethoprim-sulfamethaxazole
prophylaxis against 
 
Pneumocystis carinii
 
 pneumonia. ICL-2, ICL-3,
and ICL-8 were also taking fluconazole as prophylaxis against crypto-
coccosis. Ig isotype levels were normal in all individuals except for
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ICL-1, who had a monoclonal IgM spike on immunofixation. This
had been noted for the past seven years, without evidence for malig-
nancy. No evidence for active EBV or cytomegalovirus infection by
culture or serology was noted in any patient at the time of study.
PBMC cocultures with assay for HIV-1,2 p24 Gag antigen, and par-
ticulate reverse transcriptase in culture supernatants, and amplifica-
tion of PBMC DNA for HIV-1,-2 by PCR using 
 
gag
 
 primers (SK145
and SK431, Perkin-Elmer, Foster City, CA), performed as previously
described (1, 14), were negative.
T cell subset analysis and CD4/CD8 ratios are recorded in Table
I. All patients were followed for at least 12 mo (range 12–52 mo),
over which time they had sustained decrements in CD4 count or pro-
gressive CD4
 
1
 
 T cell loss. Controls, two females and two males age
32–44, had CD4
 
1
 
 T cell counts 
 
.
 
 1,000/mm
 
3
 
 (normal limits,
830
 
6
 
288, range 410–1,540 [15]). An additional control, a 36 year old
homosexual male, was originally reported (“Case 5”) as an instance
of ICL based upon two CD4
 
1
 
 T cell counts 
 
,
 
 300/mm
 
3
 
 and severe
 
Mycobacterium tuberculosis
 
 pneumonia (1). However, his CD4/CD8
ratio remained 
 
.
 
 1 and, 6 mo subsequent to successful antitubercule
therapy, the CD4 count returned to the low normal range. This transient
decrease in CD4 count is characteristic of a small segment of other-
wise normal individuals with pulmonary or miliary tuberculosis (5).
 
Apoptosis assays. 
 
PBMC were washed in PBS, pH 7.2, assessed
for viability by trypan blue dye exclusion, and plated at 0.5 
 
3
 
 10
 
6
 
 via-
ble cells/ml, in culture medium alone (RPMI 1640 plus 10% FBS) or
with various reagents, for 12–120 h. Cells were harvested, washed,
and labeled with anti-CD4 mAb Leu-3a, followed by exposure to
FITC-conjugated goat anti–mouse Ig. They were then fixed in 70%
cold ethanol, incubated for 20 min at 4
 
8
 
C with propidium iodide (50
 
m
 
g/ml) in the presence of RNaseA (300 U/ml) (16), and 5–10 
 
3
 
 10
 
3
 
cells were analyzed in an EPICS Elite cytofluorgraph (Coulter Immu-
nology, Hialeah, FL). Controls for antilymphocyte antibodies were
included, with no evidence for specific adherence of sera, diluted 1:20,
to autologous lymphocytes.
Apoptosis was recognized or quantitated in viable, fluorescence-
positive cells by two flow cytometric methods: detection of depressed
forward scatter and increased right angle (side) scatter characteristic
of apoptotic cells (17) and computer-assisted DNA histogram analy-
sis of propidium iodide–labeled cells with calculation of A
 
o
 
 peaks (16,
18). All experiments involved at least two patient samples obtained
 
$ 
 
2 mo apart, with A
 
o
 
 values usually varying by 
 
#
 
15%.
Parallel cell aliquots were analyzed for fragmentation of genomic
DNA. Low molecular weight DNA was prepared by lysis of 2 
 
3
 
 10
 
6
 
cells per condition in 0.4 ml of lysis buffer, consisting of 10 mM Tris-
HCl, pH 7.5, 0.2% Triton X-100, and 1 mM EDTA, followed by cen-
trifugation and precipitation of the supernatant with 0.1 ml 5 M NaCl
and 0.5 ml isopropanol overnight at 
 
2
 
20
 
8
 
C (10, 19, 20). Samples were
microcentrifuged, pellets washed with 70% ethanol, and air dried.
The DNA was then resuspended in Tris-EDTA buffer and treated
with RNase A (50 
 
m
 
g/ml) for 1 h at 37
 
8
 
C. Samples were electropho-
resed through 1% agarose gels at 50 V/25 mA for 3 h, with bands vi-
sualized by ethidium bromide (0.5 
 
m
 
g/ml) staining and photography.
Features of apoptotic cells were also directly visualized. Staining
of nucleic acid with acridine orange at low pH can discriminate
among viable, apoptotic, and necrotic cells (17). This metachromatic
dye intercalates into double-stranded DNA to fluoresce green, and
denatured (single-stranded) DNA and RNA to fluoresce red (17).
Cells were fixed as described for FACS
 
®
 
 analysis, washed, resus-
pended in 0.1 ml PBS, and transferred onto glass slides by cytocentri-
fugation. Slides were then fixed overnight at room temperature in a 1:9
solution of glacial acetic acid and absolute ethanol, air dried, and
treated with 2–3 drops of a 2% solution of Triton X-100 for 2 min. Af-
ter washing with PBS, 2–3 drops of an 8 
 
m
 
g/ml solution of acridine or-
ange in 1 N NaOH was added for 1 min, and the slides were washed
with PBS, and cells observed and photographed using an ultraviolet
light–illuminated microscope.
 
Fas and Fas ligand expression. 
 
Fas (APO-1, CD95) and Fas ligand
(FasL) expression was determined by reverse transcriptase (RT)-
PCR. Oligodeoxynucleotide primers capable of amplifying a segment
from nucleotides 271–820 of Fas cDNA (21) or nucleotides 392–1182
of FasL cDNA (22) were used: Fas: Fas-1: 5
 
9
 
-CAAGTGACTGAC-
ATCAACTCC and Fas-2: 5
 
9
 
-CCTTGGTTTTCCTTTCTGTGC;
FasL: No. 13203: 5
 
9
 
-CAGCTCTTCCACCTACAG and No. 13206:
5
 
9
 
-TCATGCTTCTCCCTCTTCACATGG. 
Total cellular RNAs were isolated from 2 
 
3
 
 10
 
6
 
 cells/sample by
the TriZOL (GIBCO BRL, Gaithersburg, MD) method (21). RNAs
were treated with RNase-free DNase, then reverse transcribed into
cDNA, using an MuLV reverse transcriptase (GIBCO BRL). Ali-
 
Table I. Summary of Case Histories and DNA Histogram Analysis
 
Subject Age/sex
Risk factors for
retroviral infection Clinical findings
Lymphocyte phenotype per mm
 
3
 
Cell cycle Analysis
CD4
 
1
 
CD8
 
1
 
CD4/CD8
ratio
CD4
 
1
 
 apoptotic peak*
peak (A
 
O
 
)
 
percent
 
ICL-1 44/M Needlestick;
 
Herpes zoster
 
, intractable 124 125 0.99 43.8
bisexual papillomatosis,
Bowen’s disease
ICL-2 35/F Needlestick Cryptococcal meningitis 100 1200 0.08 39.0
ICL-3 55/M Worker, Cryptococcal 73 350 0.21 3.8
biohazardous meningitis, B cell
waste disposal co. lymphoma
ICL-4 32/M None
 
Herpes simplex
 
, fever 110 244 0.45 33.8
ICL-5 43/F None
 
Pneumocystis carinii
 
120 133 0.90 39.9
pneumonia
ICL-6 27/M None Cryptococcal meningitis 22 51 0.43 19.4
ICL-7 35/F Needlestick Thrush, progressive, 157 365 0.43 19.2
global dementia
ICL-8 34/F None Cryptococcosis 104 100 0.96 30.7
* Determined by DNA histogram analysis of CD4
 
1
 
 T lymphocytes in PBMC maintained in culture for 72 h in the absence of exogenous stimuli.
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quots of the cDNA were then amplified by PCR, as described from
our lab (14), using Fas, FasL, or 
 
b
 
-actin (sense: 5
 
9
 
-TGACGGGGT-
CACCCACACTGTGCCCATCTA; antisense: 5
 
9
 
-CTAGAAGCA-
TTTGCGGTGGACGATGGAGGG; Stratagene Inc., La Jolla, CA)
primers. Briefly, 50 
 
m
 
l of reaction volume, including 1 
 
3
 
 reaction
buffer (Perkin-Elmer), optimized concentrations of MgCl
 
2
 
, dNTP
and primers, and 2 units of Taq polymerase were used. The cDNAs
were denatured for 2 min at 97
 
8
 
C before 35 runs in a thermal cycler,
with denaturation at 94
 
8
 
C for 1 min, annealing at 55
 
8
 
C for 1 min, and
extension at 72
 
8
 
C for 1 min in each cycle. A final extension at 72
 
8
 
C
for 5 min was included. PCR products were separated by electro-
phoresis in a 1.4% agarose gel, visualized by ethidium bromide stain-
ing under ultraviolet illumination, and photographed. The expected
sizes of the amplicons were: Fas, 549 nucleotides; FasL, 790; and
 
b
 
-actin, 661.
The identity of the FasL product was confirmed by southern blot-
ting (22) using an internal probe (5
 
9
 
-CAGCCCAGTTTCATT-
GATC). No cross-over in terms of detection of TNF-
 
a
 
 receptor or
TNF-
 
a
 
 expression was seen with these Fas and FasL primers, respec-
tively.
Both Fas and FasL determinations were performed on nonadher-
ent PBMC, prepared as described (14). Control populations of neu-
trophils and monocytes constitutively express high levels of Fas (23,
24), whereas resting CD4
 
1
 
 T lymphocytes have much less Fas expres-
sion (25). FasL is expressed on normal antigen-presenting cells (26).
 
Fas function. 
 
The lysis of a clone of 
 
51
 
Cr-labeled, CD4
 
1
 
, Fas
 
1
 
Jurkat T cells, having very low baseline FasL expression, was quanti-
tated following exposure to ICL or control PBMC. These Jurkat cells
are highly sensitive to lysis following Fas cross-linking but are resis-
tant to other potential confounding factors such as cytokine-mediated
apoptosis (24). The functional meaning of changes in FasL was ex-
plored using a panel of mAbs directed to Fas, generated by immuniz-
ing mice with a purified fusion protein consisting of the extracellular
domain of human Fas and the constant region of human IgG
 
1
 
 (13).
When added in solution, Fas mAb M3 blocks Fas-mediated cell lysis,
whereas Fas mAb M31 binds to the antigen but has no agonistic or
antagonistic properties (24, 27). 1 
 
3
 
 10
 
4
 
 Jurkat cells, labeled for 3 h
with 
 
51
 
Cr as described (24, 27), were added to varying numbers of ef-
fector cells (1:1 to 25:1) in 0.2 ml of culture medium in 96-well round
bottom plates. All conditions were established in triplicate. Anti-Fas
mAbs were included in certain experiments. After overnight culture
at 37
 
8
 
C, 100 
 
m
 
l of supernatant were harvested from each well, and
 
51
 
Cr release determined in a gamma counter. Percent specific killing
was calculated according to the formula: 100 
 
3
 
 [(
 
experimental cpm
 
) 
 
2
 
(
 
spontaneous cpm
 
)]/[(
 
maximum cpm
 
) 
 
2 
 
(
 
spontaneous cpm
 
)], where
spontaneous cpm is the counts per min released in medium alone, and
maximum cpm is the radioactivity released in the presence of 1% Tri-
ton X-100. Spontaneous release represented 7–15% of maximal
counts released.
 
Histone antibody analyses. 
 
An ELISA for antihistone antibodies
in sera of control and ICL patients, using H1, H2A, and H2B histone
preparations from calf thymus (Worthington Biochemicals, Malvern,
PA), was performed by standard techniques. Human sera were di-
luted 1:200, rabbit anti–human Ig diluted 1:2,000 and adsorbed over-
night with all histone preparations, and horseradish peroxidase–con-
jugated goat anti–rabbit Ig used at a dilution of 1:500 (Kirkegaard
and Perry, Gaithersburg, MD). Each microtiter well of the ELISA
plates was coated with 
 
z 
 
10 ng of the appropriate histone preparation.
 
Results
 
Apoptosis in CD4
 
1
 
 T lymphocytes from ICL patients. 
 
Fluores-
cent-labeled CD4
 
1
 
 T lymphocytes in PBMC derived from
seven of eight ICL patients with a history of opportunistic in-
fections exhibited apoptosis exceeding control levels. This was
first noted by the criterion of low DNA staining, represented
by a pre-G
 
1
 
 A
 
o
 
 peak that occupied from 19 to 
 
.
 
 40% of the
DNA histogram (Table I). Three control donors gave no evi-
dence for such cell death. These data were obtained after a 72-
h culture of PBMC in the absence of exogenous stimuli. At
least 12 h of culture was required to detect an A
 
o
 
 peak. Ex-
tended culture periods resulted in an increase in A
 
o
 
 area for all
patients, as described in a subsequent experiment. The one in-
dividual, ICL-3, who did not display accelerated apoptosis still
had an A
 
o
 
 peak in the control range after prolonged culture
(
 
,
 
 10% at 120 h).
Examples of the DNA histograms used to derive the A
 
o
 
values of Table I are presented in Fig. 1. The A
 
o
 
 peaks for two
representative patients, ICL-2 and ICL-7, with profound CD4
 
1
 
T cell depletion accompanied by normal numbers of CD8
 
1 T
cells, are outlined for both total PBMCs and labeled CD41 T
cells. These histograms illustrate the fact that apoptosis appears
to be limited to the CD41 T cell population in these two indi-
viduals, with a marked disparity between the Ao peak of CD41
cells vs. unselected cell populations (, 4%, Fig. 1) or isolated
CD81 cells (, 5%, data not shown). Three of three controls
gave , 3% apoptosis in all cell populations. In contrast, ICL-1,
with decreases in absolute numbers of both CD41 and CD81
T cells, showed equivalent levels of accelerated apoptosis in
both lymphocyte subpopulations (data not shown).
Fig. 2 presents another criterion for apoptosis, changes in
light scatter, along with DNA histograms for a control and two
ICL patients. In these experiments, a longer period of culture
was used so as to be able to determine the impact of mitogenic
stimulation on apoptosis. The majority of unstimulated ICL
CD41 T cells demonstrate an apoptotic pattern with de-
pressed forward light scatter (Fig. 2), secondary to cell shrink-
age, and elevated side scatter (not shown) due to chromatin
condensation with resultant increased granularity. Propidium
iodide staining of genomic DNA from fixed aliquots of the
same cell populations revealed prominent Ao regions of low
DNA staining, comprising up to 70% of the Leu-3a1 (CD41)
T cell population in patients but , 20% in controls. (Note that
the additional culture period led to a general increase in apop-
totic index [compare data for patients ICL-4 and ICL-5 in Ta-
ble I and Fig. 2].) Ao rose to . 80% in some samples after ex-
posure to the mitogen phytohemagglutinin (PHA, 5 mg/ml;
Fig. 2) or anti-CD3 mAb (100 ng/ml; data not shown) in pa-
tient but not control samples. This is consistent with the fact
that T cell receptor triggering of cells preprogrammed for
apoptosis facilitates endonucleosomal cleavage (18).
Apoptosis was confirmed by direct observation of differen-
tial staining of double-stranded vs. denatured, condensed
DNA after exposure to acridine orange (data not shown). It
was recognized before disruption of plasma membranes, with
trypan blue dye exclusion viability . 85% in all samples.
In contrast to these results, apoptosis above control levels
was not seen in unstimulated or PHA-activated PBMC from a
donor with transient T lymphopenia (“case 5” [1]), tested
when his CD4 counts were in the 300/mm3 range as well as af-
ter their rise to . 600/mm3. The Ao region of CD41 cells was
11.5% at 96 h of culture, similiar to that of controls at this time
point (, 10%). Comparable values were obtained for two
other individuals diagnosed as having ICL based solely upon
stable CD41 T cell counts , 300/mm3 over several years (not
shown). As for case 5, their CD4/CD8 ratios were . 1, and
they had no clinical signs or symptoms of immune deficiency.
This suggests a physiologic T cell lymphopenia, rather than an
ongoing pathologic process, in these donors (5).
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DNA fragmentation was further documented by electro-
phoresis of low molecular weight DNA extracted from ICL
PBMCs. Oligonucleosomal units were visible as bands whose
molecular sizes are approximate multiples of 180 nucleotides
in only one sample, where sufficient cell numbers were avail-
able to obtain an adequate quantity of DNA. In the remaining
samples, an increase in low molecular weight DNA was seen,
but distinct laddering could not be visualized.
Inhibition of ICL associated apoptosis in vitro. We exam-
ined the susceptibility of these apoptotic processes to potential
inhibitors of two major pathways for programmed cell death:
Ca21-dependent endonucleases that cleave host chromatin in
the nucleosomal linker regions, and nuclease induction via a
Ca21-independent, cAMP-directed mechanism (28). Two mol-
ecules with divergent mechanisms of action and potential clini-
cal utility were selected. At 50–100 mM, monomeric and poly-
meric aurintricarboxylic acid (C22H14O9) inhibits a variety of
enzymes that process nucleic acids, including RNA and DNA
polymerases, reverse transcriptase, integrase, and exo and en-
donucleases (29). At lower concentrations (, 3 mM), ATA
continues to suppress Ca21-mediated endonuclease induction
and, as such, has proven a potent inhibitor of apoptosis in cells
as disparate as thymocytes (20) and TNF-a stimulated mam-
mary adenocarcinoma (30). Tamoxifen citrate (1-[p-dimethyl-
amineorthoxyphenyl]-1, 2-diphenyl-1-butene) is an estrogen
antagonist having no effect on nucleases but capable of sup-
pressing calmodulin, cAMP, and protein kinase A (PKA) induc-
tion at clinically attainable doses (1–2.5 mM) (16, 31). cAMP/
PKA inhibitors block several triggers to apoptosis in T lympho-
cytes, independent of Ca21 flux (32). TMX, as its 5-hydroxy
derivative, has recently been shown to block apoptosis in some
cell types (33).
PBMC from four of the seven ICL patients exhibiting ac-
celerated apoptosis, when exposed to ATA or TMX or both,
had a $ 50% decrease in apoptotic index, with improvement
in light scatter patterns, concomitant with suppression of the
Ao peak (Fig. 2 and Table II). Together with IL-2, concentra-
tions of ATA as low as 0.01 mM suppressed Ao by . 40%, with
maximal effect at 0.1 mM (60–90% inhibition). TMX gave an
IC50 for inhibition of the Ao peak in both unstimulated and
PHA-treated ICL CD41 T cells of 0.25 mM, with maximal
suppression at 1 mM (Fig. 2). These results were confirmed by
DNA electrophoresis. DNA extracted from ICL PBMC
treated with ATA or TMX showed suppression of the low mo-
lecular weight fraction of DNA as compared to samples from
cells cultured in the absence of drugs (data not shown).
Preexistence of apoptotic mechanisms in ICL. Activation-
induced death of CD41 T cells from HIV-11 individuals is en-
hanced by calcium ionophores (34) and blocked by the protein
synthesis inhibitor cycloheximide (10, 34), while spontaneous
apoptosis in unstimulated HIV1 cultures is unaffected by sup-
pression of protein or RNA synthesis (34). We investigated
these phenomena in ICL. Ca21 mobilization after exposure of
ICL PBMC to A23187 (1 mM) for 24 h. led to an increase in
DNA fragmentation, while phorbol myristate acetate (5 ng/
ml) and cycloheximide (0.5 mg/ml) did not alter spontaneous
apoptosis (data not shown). This is similar to effects in PBMC
from HIV1 patients and suggests that T cells from ICL pa-
tients possess the complete machinery necessary for acceler-
ated cell death.
Fas and FasL expression. RT-PCR amplification of Fas
and Fas ligand mRNA in unstimulated normal donor and ICL
cells was performed on aliquots of RNA. Fas was present at
very low levels in unstimulated, adherent cell–depleted control
Figure 1. Comparison of DNA histo-
grams for CD4 negative cells vs. CD41 
T lymphocytes in PBMCs derived from 
ICL patients. , 4% of CD4 negative 
cells from patient ICL-2 and , 2% of 
such cells from patient ICL-7 were in 
the apoptotic, Ao portion of the cell cy-
cle (lightly shaded, computer-generated 
peak) after 72 h of culture, while 39.9% 
of CD41 cells from ICL-2 and 19.2% 
from ICL-7 were apoptotic by this crite-
rion at this time point.
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PBMC samples (Fig. 3 A), but was present in high levels in all
of eight ICL patients evaluated (Fig. 3 B), despite no observ-
able difference in levels of b-actin expression in these samples
(Fig. 3, A and B). Two bands, the larger of anticipated size and
the smaller, confirmed as a Fas product by southern blotting
and presumably representing a transmembrane domain-trun-
cated form, was also noted in all ICL samples (Fig. 3 B). Using
1 mg of total RNA, no or very weak signals for FasL were seen
Figure 2. Spontaneous and mitogen-induced apoptosis in CD41 T lymphocytes from ICL patients. Flow cytometric data profiles depict propid-
ium iodide DNA staining (PMT1, y axis) versus forward light scatter (FS, x axis), as well as DNA histograms (cell number, y axis, vs. propidium 
iodide DNA staining [PMT4], x axis), of FITC-labeled CD41 T cells. PBMCs were obtained from two ICL patients, ICL-4 (LH) and ICL-5 
(CR), and donor Control-1 (LN), and examined in the absence of stimuli and after culture with IL-2 (20 U/ml) or PHA (5 mg/ml). All cultures 
were maintained for 120 h. The percent DNA staining in the Ao region is given in the upper right quadrant of each DNA histogram. Experi-
ments were performed in the absence (a) or presence (b) of ATA or TMX. The latter also all contain IL-2 (20 U/ml).
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in adherent cell–depleted PBMC from two normal control do-
nors (Control-1 and -2, Fig. 3, C and A, respectively) and from
a control donor with physiologic CD4 lymphopenia (Control-
3, Fig. 3 A). In contrast, in six of eight ICL patients, intense bands
for FasL were seen (Fig. 3 C and additional data not shown).
Neither ATA nor TMX had any impact on expression of Fas
(not shown), but they did block FasL expression (Fig. 3 C).
Fas-mediated apoptosis. An assay of FasL function was
next performed. As shown in Fig. 4, PBMC from two ICL pa-
tients expressing FasL by RT-PCR, ICL-4 and ICL-6, but not
Table II. Effect of Various Agents on ICL-associated CD41 T Cell Apoptosis In Vitro
Condition* percent apoptosis (AO peak)
Subject Buffer IL-2 ATA 1 TMX IL-2 1 ATA 1 TMX IL-2 1 ATA IL-2 1 TMX
Control-1 0 0 0 0
Control-2 0.6 0.7 0 0
Control-3 0 0 ND 0
ICL-1 43.8 8.6 2.5 3.8
ICL-2 39.0 45.4 54.7 54.9
ICL-3 3.8 2.0 0 0
ICL-4 63.8 94.2 ND ND 24.9 37.7
ICL-5 71.7 86.5 ND ND 29.7 ND
ICL-6 19.4 13.3 9.7 2.9
ICL-7 19.2 8.8 14.1 12.0
ICL-8 30.7 18.5 — 15.4
* IL-2: 20 U/ml nonrecombinant; ATA: 0.1 mM; TMX: 1 mM. PBMC placed in culture for 3 d before staining with anti-CD4 mAb and propidium io-
dide, except for ICL-4 and ICL-5 which were cultured for 5 d.
Figure 3. RT-PCR for expression of Fas and Fas ligand. Control (C; A and C) and ICL (B and C) PBMC were maintained in culture for 72 h in 
the absence or presence of 1 mM ATA 1 1 mM TMX 1 IL-2 (inhibitors). RNA derived from these cultures was reverse transcribed into cDNA, 
and the products amplified by PCR using the Fas or FasL primers described in the text. b-actin mRNA levels were simultaneously determined as 
a control for RNA integrity in these samples. (A) M, markers; lanes 1,2: FasL amplification; lanes 3,4: Fas amplification; lanes 5,6: b-actin ampli-
fication.
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PBMC from Control-1, who did not express elevated FasL
(Fig. 3 C), gave a high degree of specific killing of 51Cr-labeled
CD41 Jurkat T cell targets. This killing was blocked by solu-
ble anti-Fas mAb M3, but not by anti-Fas mAb M31, which
does not interfere with Fas cross-linking.
In agreement with these data, soluble anti-Fas mAb M3 de-
creased the Ao peak of spontaneous apoptosis when added to
ICL PBMC cultures on their initiation, while an anti–TNF-a
polyclonal rabbit anti–human neutralizing antiserum (Gen-
zyme Corp., Cambridge, MA) had no or little effect. For ex-
ample, apoptosis occurring after 72-h cultures, as measured by
percent Ao peak, was 31.2% for ICL-6 PBMC alone, 30.8% in
the presence of 1,000 neutralizing U/ml of anti–TNF-a, but
18.2% in the presence of 10 mg/ml M3 mAb. Similarly, ICL-2
gave 26.6% baseline apoptosis, 23.4% in the presence of anti–
TNF-a, and , 1% with M3 mAb.
Antihistone reactivity in ICL sera. We detected IgG anti-
histone antibodies to histone H2B in sera from three of our
eight ICL patients. (ICL-1,4,6), with optical density readings .
three times the standard deviation of controls. 10 control sera
and sera from two donors with physiologic lymphopenia
showed no reactivity above background with H2B (mean OD
0.1060.01).
Discussion
Accelerated apoptosis of CD41 T lymphocytes was docu-
mented in seven of eight patients with a subtype of ICL, as
characterized by persistent CD4 lymphopenia, CD4/CD8 ratios
, 1, and evidence for clinical immune deficiency. Apoptosis
was demonstrated by three different methods: laser-illumi-
nated light scatter; DNA labeling and quantitation of the pre-
G1 Ao peak; and direct visualization of chromatin fragmenta-
tion by DNA agarose gel electrophoresis. The use of multiple
confirmatory assays for apoptosis was undertaken as there
may not be a direct correlation between any single assessment
of apoptosis and all the morphologic and genomic criteria for
this type of programmed cell death (35).
Evidence for an in vivo role for apoptosis in this subset of
ICL comes from three types of data. First, the low CD4 counts
in one donor, “case 5,” originally classified as having ICL
solely on the basis of two CD4 counts , 300/mm3, returned to
normal after treatment of an M. tuberculosis infection, and this
donor, as two others with stable low CD4 counts, showed no
evidence for apoptosis at any level of absolute CD4 cell count.
Second, we detected antihistone autoantibodies, presumably
induced by fragmented chromatin, in some of these sera, with
reactivity predominantly to type H2B, a pattern identical to
that found in HIV disease (12, 36) and simian immunodefi-
ciency virus infection in macaques (37), both of which have
been associated with CD41 T cell apoptosis: in vitro in the
case of HIV (10, 11), and in vivo in macaques (37). Third, de-
tection of apoptosis among CD81 T cells appeared to corre-
late with their depletion in vivo, occurring in those ICL pa-
tients with low levels of both CD41 and CD81 T cells.
It is unlikely that a single pathophysiology will be operative
in ICL. However, the mechanism of accelerated T cell death in
at least some of our patients may relate to the enhanced sus-
ceptibility of Fas-expressing T lymphocytes to cross-linking by
Fas ligand. Fas, a 48-kD polypeptide belonging to the family of
type I plasma membrane receptors, appears to play a central
role in the regulation of apoptosis. Quiescent PBMCs express
Fas at low levels or not at all (38). While expression is mark-
edly increased after mitogen activation of primary T cells, un-
like T cell lines they are not induced to undergo apoptosis
when Fas is cross-linked with an anti-Fas mAb or FasL. This
process requires restimulation after chronic T cell receptor ac-
tivation (39). Indeed, rather than initiating cell death, many
anti-Fas mAbs act as potent costimulators of normal T cell
proliferative responses to mitogen and antigen (39). In con-
trast to primary cells from normal donors, Fas is increased on
T cells from many HIV-11 individuals (25, 40), and HIV in-
fected cell lines are highly sensitive to the cytolytic activity of
certain anti-Fas mAbs (41). The ligand for Fas, a type II trans-
membrane protein, can induce apoptosis in Fas-expressing tar-
gets, as shedding of overexpressed protein actively triggers cell
death by Fas binding (21). Fas/FasL interactions apart from cy-
tolytic T cell activity appear to be physiologically important, as
point mutations in the FasL gene result in accumulation of
large numbers of T cells in the lymphoid tissues of affected
mice (22).
Evidence for elevated Fas and FasL in ICL could be inter-
preted as merely indicating the presence of preactivated cells.
The potential functional significance for the sustained expres-
sion of FasL in ICL was thus explored. CD41 Jurkat T cells
are lysed in the presence of Fas ligand but are resistant to
TNF-a–induced apoptosis (21). They were specifically lysed by
coculture with unstimulated PBMC from ICL patients ex-
pressing elevated levels of FasL mRNA. Killing was blocked
by soluble anti-Fas mAb M3. Whether this phenomenon oc-
curs via receptors and ligands expressed by the same cell (in
cis) or by different cells (in trans) and whether cell contact or
soluble FasL or both is involved was not addressed.
The single patient showing little apoptosis also did not ex-
press FasL (ICL-3). However, Fas/FasL interactions cannot be
the only mechanism of apoptosis in our ICL patients. For ex-
ample, ICL-4, with high levels of apoptosis, had minimal ex-
pression of FasL mRNA. It should also be noted that ICL sam-
ples gave not only the Fas product of expected size (arrow, Fig.
3 B) but also a distinct smaller fragment (Fig. 3 B). By size this
appears to be a truncated, soluble form of Fas, normally seen
at low levels, but reported to be present in high levels in sys-
Figure 4. Fas ligand-expressing cells from ICL patients are active in a 
bioassay for FasL activity. 51Cr-labeled Jurkat CD41 T cells targets 
were cultured for 18 h with ICL patient or control PBMCs, either 
alone or in the presence of soluble Fas mAb M3 (solid triangles) or 
Fas mAb M31 (not shown).
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temic lupus erythematosis (42). We are currently investigating
the relative levels of these two products in ICL. It should be
emphasized, however, that there was no evidence in our ICL
patients for retroviral infection, active infection with other vi-
ruses known to cause apoptosis, or for autoimmune diseases
such as systemic lupus, which have been linked to both CD41
T cell loss (43) and accelerated apoptosis in vitro (44).
There are several similarities between apoptosis occurring
among CD41 T cells from HIV1 and ICL patients. These in-
clude its enhancement by T cell activators, its independence
from new protein synthesis, and its susceptibility to general in-
hibitors of programmed cell death. In addition, both Fas and
FasL appear to be elevated on T lymphocytes from many pa-
tients with both disorders. One obvious difference is the direct
involvement of HIV in some apoptotic T cells (12). This find-
ing has been challenged, however, by recent data indicating
that it is predominantly bystander T cells, and not productively
infected cells, that undergo apoptosis in HIV/AIDS (11). In
addition, many studies show equivalent levels of apoptosis
among both CD41 and CD81 T cells from HIV1 donors, re-
gardless of their absolute levels of CD81 peripheral T cells. In
contrast, the two ICL patients we investigated with normal ab-
solute numbers of CD81 T cells had evidence for apoptosis
only among the CD41 T subset. Our limited sample size pre-
cludes an absolute statement in this regard, however.
12–24 h of culture were required before changes in Ao peak
or fragmentation of DNA could be visualized. This lag has also
been seen with PBMC isolated from AIDS patients (11, 45)
and may relate to the fact that fully apoptotic cells would be
rapidly and efficiently removed from the circulation, whereas
cells programmed for such death require some interval for ex-
pression of the full phenotype. 
The exact process by which ATA and/or TMX, in conjunc-
tion with IL-2, blocked apoptosis in T cells from some ICL pa-
tients, most prominently in ICL-1, ICL-4 and ICL-5, but not
others is unclear. Given the ability of ATA and TMX to sup-
press two activities integral to endonucleosomal DNA cleav-
age in apoptosis, Ca21-mediated endonuclease activation and
cAMP/PKA induction, respectively, these represent possible
mechanisms of action. It should be noted, however, that ATA
is a potent antiapoptotic agent even in anucleate CD41 T cells
(46), so that its mechanism of action cannot yet be established
with any certainty. In addition, TMX can drive cells into G0,
and may thus protect them simply by reducing their activation
state (16). We have also shown that ATA plus TMX can block
FasL, but not Fas, expression, and this may be related to the
apoptotic suppression observed. There is precedent for such a
mechanism, as two agents which can inhibit apoptosis in
murine T lymphocyte hybridomas, retinoic acid and glucocor-
ticoids, block upregulation of FasL (47). IL-2 has also been as-
sociated with partial suppression of apoptosis linked to a vari-
ety of factors, from glucocorticoid exposure (48) to HIV
infection (49).
Finally, the severity of disease in subsets of individuals with
ICL, such as those presented here, should not be underesti-
mated. Albeit the prevalence of ICL among unselected popu-
lations is very low, usually transient, and most often associated
with a recent illness (5, 50), opportunistic infections and other
disorders frequent in or pathognomonic of AIDS caused the
death of three of our original five ICL patients (1). A similar
high death rate was reported by the Italian Study Group on
Non-HIV AIDS (51). The ability of ATA or TMX or both, in
combination with IL-2, to inhibit common pathways for apop-
tosis in ICL in vitro should encourage studies of such agents in
the treatment of clinically significant idiopathic CD41 T lym-
phocytopenias.
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